Cell Signaling | Neuronal Signaling Mechanisms | Pharmacogenomics | Drug Discovery & Design | Neuropharmacology & Psychopharmacology | Molecular Pharmacology
Human clinical ketamine response correlates with glutamine metabolism in cultured activated lymphocytes and in-vivo hepatic glycine metabolism
Jon Berner*
*Corresponding author: Jon Berner
Woodinville Psychiatric Associates, Woodinville, WA, USA
F1000Posters 2011, 2: 516 (poster) [ENGLISH]
Poster [764.41 KB]
Presented at
66th Society of Biological Psychiatry Annual Meeting 2011,
11 - 13 May 2011, 308
NMDA antagonists are useful agents in a variety of syndromes but optimal patient selection and dosing is still relatively unexplored. Biomarkers may help to advance the current clinical understanding of the nonspecific NMDA antagonist, ketamine, and guide the practical development of the more specific NR2A and NR2B antagonists.
We found in a retrospective review of 40 clinical trials with ketamine that clinical response correlated with PHA stimulated lymphocyte growth response in a glutamine limited bath and the fasting serum glycine to serine ratio.
This data has direct application to known effects of NR2B stimulation on p38 MAPK activity and, given extracellular glutamine concentration effects on leucine uptake, also on background MTOR activity.
No relevant conflicts of interest declared.
Please note that most posters on this site present work that is preliminary in nature and has not been peer reviewed.
This poster is open access subject to the CC BY-NC Creative Commons 3.0 License
